Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study

Abstract Introduction Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission tomography (PET) may identify those pati...

Full description

Bibliographic Details
Main Authors: E. A. van de Stadt, M. Yaqub, A. A. Lammertsma, A. J. Poot, P. R. Schober, R. C. Schuit, E. F. Smit, I. Bahce, N. H. Hendrikse
Format: Article
Language:English
Published: SpringerOpen 2020-08-01
Series:EJNMMI Research
Subjects:
[18F] Afatinib
NSCLC
EGFR TKI
PET/CT
Targeted therapy
Lung cancer
Online Access:http://link.springer.com/article/10.1186/s13550-020-00684-4

Internet

http://link.springer.com/article/10.1186/s13550-020-00684-4

Similar Items